



## **Anaphylaxis: Protector Become the Eater**

*Rohit Dighe , Laxman Pawar , Nityanandi Sapkale*

Mahavir Institute of Pharmacy, Nashik

---

### **ABSTRACT:**

Anaphylaxis is a serious, life-threatening allergic reaction that usually occurs within a few seconds or minutes of exposure to allergic substances. It involves symptoms such as skin reactions like itching and hives, flushed and pale skin, lower blood pressure, difficulty breathing, choking, weak and rapid pulse rate, vomiting, nausea, and dizziness or fainting<sup>1</sup>.

The main cause of anaphylaxis is exposure to an allergic substance. This may include food products such as peanuts, tree nuts, fish, shellfish, and milk. Some medications including antibiotics (especially penicillin group and sulpha containing) can also trigger the disease. Stings from bees, wasps, latex are also involved. Some sort of aerobic exercises can also trigger anaphylaxis in some people.

Anaphylaxis is an emergency and needs to be rushed to medical care. Treatment options include adrenaline (also known as epinephrine) to reduce the allergic response, intravenous antihistamines to relieve itch and hives, and beta-agonists like albuterol (also known as salbutamol) to relieve breathing problems.

Prevention methods include avoiding substances that trigger the reaction, wearing long-sleeved dresses, avoiding walking on bare feet, avoiding perfumes or scented lotions which attract insects, and reading the labels of all food ingredients to prevent a food allergy<sup>1</sup>. If you or someone you know is exhibiting symptoms of Anaphylaxis, seek medical attention immediately

---

### **Introduction :**

Anaphylaxis is a severe, life- hanging antipathetic response. It can be seconds or twinkles after you 've been exposed to commodity you 're antipathetic to. Peanuts or freak stings are exemplifications. In anaphylaxis, the vulnerable system releases a flood tide of chemicals that can beget the body to go into shock. Blood pressure drops suddenly, and the airways narrow, blocking your breathing. The palpitation may be fast and weak, and you may have a skin rash. You may also get squeamish and heave. Anaphylaxis needs to be treated right down with an injection of epinephrine. However, it can be deadly, If it is n't treated right down. Anaphylaxis is a severe, potentially life- hanging antipathetic response. It can do within seconds or twinkles of exposure to commodity you are antipathetic to, similar as peanuts or freak stings. Anaphylaxis causes the vulnerable system to release a flood tide of chemicals that can beget you to go into shock — blood pressure drops suddenly and the airways narrow, blocking breathing. Signs and symptoms include a rapid-fire, weak palpitation; a skin rash; and nausea and vomiting. Common triggers include certain foods, some specifics, nonentity venom and latex. Anaphylaxis requires an injection of epinephrine and a follow- up trip to an exigencyroom. However, you need to go to an exigency room incontinently, If you do not have epinephrine. However, it can be fatal, If anaphylaxis is not treated right down.

---

### **Body --**

The immune system plays a crucial role in anaphylaxis. Anaphylaxis is a severe, life-threatening, generalized or systemic hypersensitivity reaction<sup>1</sup>. It is caused by a problem with the immune system, which overreacts to a harmless substance and releases a number of different chemicals, such as histamine, to deal with the mistaken threat.

Here's how it works:

The immune system identifies a foreign substance (an antigen) as a threat and prepares cells to fight it.

This process involves T-helper cells, which turn into Th2 cells. These Th2 cells release proteins called interleukins.

Interleukins interact with B cells to produce infection-fighting antibodies that bind to mast cells<sup>3</sup>. These mast cells contain chemical particles they'll release in the presence of an antigen<sup>3</sup>.

Interleukins also activate eosinophils, a type of white blood cell that discharges toxic substances to destroy invading cells.

After initial exposure, the mast cells activated during this phase are still equipped with allergen-specific antibodies and remain combat-ready, prepared to respond immediately should a second exposure ever occur.

If two or more allergen molecules bind to a sensitized mast cell, the mast cell releases inflammatory mediators that produce an allergic reaction. These mediators include substances like histamine and more of the interleukins that, in turn, activate eosinophils, Th2 cells, and basophils (another type of white blood cell).

It's important to note that anaphylaxis results from the actions of a wide range of mediators released by mast cell and basophil degranulation<sup>1</sup>. Many of these mediators are preformed and stored in the granules, whereas others are produced *de novo* on activation of mast cells and basophils. Degranulation can be mediated by cross-linking of IgE bound to membrane high-affinity IgE receptor (FcεRI), or by non-IgE-mediated mechanisms

Anaphylaxis is a severe allergic reaction that involves the release of various chemicals by the immune system. These chemicals are released in response to exposure to an allergen, which the immune system mistakenly identifies as a threat.

The chemicals involved in anaphylaxis include:

**Histamine:** This is a natural chemical released by the immune system that causes inflammation. It's responsible for many of the symptoms of an allergic reaction, such as itching, redness, and swelling<sup>3</sup>.

**Arachidonic acid metabolites:** These are products of arachidonic acid, a fatty acid that's involved in the inflammatory response.

**Chemokines:** These are small proteins that guide the movement of immune cells to the site of inflammation.

**Cytokines:** These are proteins that are important in cell signaling. They can stimulate the movement of cells towards sites of inflammation.

**Proteases:** These are enzymes that break down proteins and peptides.

**Proteoglycans:** These are compounds consisting of a protein bonded to glycosaminoglycan chains. They're involved in regulating the behavior of cells.

These chemicals cause a range of symptoms, including skin reactions (like hives and itching), low blood pressure, constriction of the airways (which can cause difficulty breathing), a weak and rapid pulse, nausea, vomiting, and dizziness or fainting. If not treated immediately, anaphylaxis can be fatal. Treatment typically involves an injection of epinephrine (also known as adrenaline), which can counteract many of the effects of these chemicals

---

## Conclusions:

In conclusion, anaphylaxis is a serious medical condition that requires immediate attention. Understanding its causes and symptoms can help in its prevention and treatment. If you or someone you know is exhibiting symptoms of Anaphylaxis, seek medical attention immediately. Prevention methods include avoiding substances that trigger the reaction, wearing long-sleeved dresses, avoiding walking on bare feet, avoiding perfumes or scented lotions which attract insects, and reading the labels of all food ingredients to prevent a food allergy.

## References :

---

1. "Anaphylaxis: Confirming the diagnosis and determining the cause(s)" by Anne K Ellis, MD, MSc, FRCPC, FAAAAI1.
2. "Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis" by Marcus S. Shaker, MD, MSc<sup>2</sup>.
3. "Anaphylaxis - a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis" by Shaker MS, Wallace DV, Golden DBK
1. Bousfiha A, Jeddane L, Al-Herz W, Ailal F, Casanova J-L, Chatila T, et al. The 2015 IUIS phenotypic classification for primary immunodeficiencies. *J Clin Immunol* (2015) 35(8):727–38. doi:10.1007/s10875-015-0198-5
2. Picard C, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency 2015. *J Clin Immunol* (2015) 35(8):696–726. doi:10.1007/s10875-015-0201-1
3. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. *J Clin Immunol* (2007) 27(5):497–502. doi:10.1007/s10875-007-9103-1
4. Madkaikar M, Aluri J, Gupta S. Guidelines for screening, early diagnosis and management of severe combined immunodeficiency (SCID) in India. *Indian J Pediatr* (2016) 83(5):455–62. doi:10.1007/s12098-016-2059-5
5. Gupta S, Madkaikar M, Singh S, Sehgal S. Primary immunodeficiencies in India: a perspective. *Ann N Y Acad Sci* (2012) 1250:73–9. doi:10.1111/j.1749-6632.2011.06353.x
6. Gupta MC, Agarwal VK, Mittal AK, Rajvanshi VS. Wiskott-Aldrich syndrome. A case report. *J Assoc Physicians India* (1964) 12:531–3.

7. Mehta SR, Sarin LR, Sanghvi LM. Agammaglobulinaemia. *J Indian Med Assoc* (1964) 1(42):539–41.
8. Malaviya AN, Sachdeva KK, Singh N. Ataxia telangiectasia: immunological abnormalities in probands and first degree relatives in 5 families. *J Assoc Physicians India* (1973) 21(8):701–5.
9. Suri D, Bhattad S, Sharma A, Gupta A, Rawat A, Sehgal S, et al. Serial serum immunoglobulin G (IgG) trough levels in patients with X-linked agammaglobulinemia on replacement therapy with intravenous immunoglobulin: its correlation with infections in Indian children. *J Clin Immunol* (2017) 37(3):311–8. doi:10.1007/s10875-017-0379-5
10. Hagin D, Burroughs L, Torgerson TR. Hematopoietic stem cell transplant for immune deficiency and immune dysregulation disorders. *Immunol Allergy Clin North Am* (2015) 35(4):695–7
11. doi:10.1016/j.iac.2015.07.010 11. Kapoor N, Raj R. Hematopoietic stem cell transplantation for primary immune deficiency disorders. *Indian J Pediatr* (2016) 83(5):450–4. doi:10.1007/s12098-015-2012-z
12. Sobh A, Bonilla FA. Vaccination in primary immunodeficiency disorders. *J Allergy Clin Immunol Pract* (2016) 4(6):1066–75. doi:10.1016/j.jaip.2016.09.012
13. Gomber S, Arora V, Dewan P. Vaccine associated paralytic poliomyelitis unmasking common variable immunodeficiency. *Indian Pediatr* (2017) 54(3):241–2. doi:10.1007/s13312-017-1038-x
14. Jorba J, Diop OM, Iber J, Sutter RW, Wassilak SG, Burns CC. Update on vaccine-derived polioviruses—worldwide, January 2015–May 2016. *MMWR Morb Mortal Wkly Rep* (2016) 65(30):763–9. doi:10.15585/mmwr.mm6530a3
15. Barbouche MR, Wassilak SG, Pallansch SA, Kluglein S, Quinn J, Sutter RW, et al. Patients with primary immunodeficiencies are reservoir for neurovirulent vaccine derived polio virus strain and represent a risk to polio virus eradication initiative. Poster Presented at: 17th Biennial Meeting of the European Society for Immunodeficiencies; Sep 21; Barcelona, Spain (2016).
16. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. *JAMA* (2014) 312(7):729–38. doi:10.1001/jama.2014.9132
17. Pai S-Y, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. *N Engl J Med* (2014) 371(5):434–46. doi:10.1056/NEJMoa1401177
18. de Felipe B, Olbrich P, Lucenas JM, Delgado-Pecellin C, Pavon-Delgado A, Marquez J, et al. Prospective neonatal screening for severe T- and B-lymphocyte deficiencies in Seville. *Pediatr Allergy Immunol* (2016) 27(1):70–7. doi:10.1111/pai.12501
19. Kwan A, Puck JM. History and current status of newborn screening for severe combined immunodeficiency. *Semin Perinatol* (2015) 39(3):194–205. doi:10.1053/j.semperi.2015.03.004
20. Jindal AK, Rawat A, Suri D, Sharma M, Shandilya JK, Goel S, et al. Severe Aspergillus pneumonia and pulmonary artery hypertension in a child with autosomal recessive chronic granulomatous disease and selective IgA deficiency. *J Clin Immunol* (2017) 37(4):333–5. doi:10.1007/s10875-017-0386-6
21. Vignesh P, Suri D, Rawat A, Lau YL, Bhatia A, Das A, et al. Sclerosing cholangitis and intracranial lymphoma in a child with classical Wiskott-Aldrich syndrome. *Pediatr Blood Cancer* (2017) 64(1):106–9. doi:10.1002/pbc. 26196
22. Senapati J, Devasia AJ, David S, Manipadam MT, Nair S, Jayandharan GR, et al. Diffuse large B cell lymphoma in Wiskott-Aldrich syndrome: a case report and review of literature. *Indian J Hematol Blood Transfus* (2014) 30(Suppl 1):309–13. doi:10.1007/s12288-014-0377-1
23. Bal A, Gupta A, Sodhi KS, Das A, Singh S. Multifocal extranodal non-Hodgkin lymphoma involving both the lungs and brain in a child with primary immunodeficiency. *J Pediatr Hematol Oncol* (2008) 30(4):317–9. doi:10.1097/ MPH.0b013e318161aa3b
24. Bittles AH. The impact of consanguinity on the Indian population. *Indian J Hum Genet* (2002) 8(2):45–51.
25. Pemberton TJ, Li F-Y, Hanson EK, Mehta NU, Choi S, Ballantyne J, et al. Impact of restricted marital practices on genetic variation in an endogamous Gujarati group. *Am J Phys Anthropol* (2012) 149(1):92–103. doi:10.1002/ajpa.22101
26. Kumaramanickavel G, Joseph B, Vidhya A, Arokiasamy T, Shridhara Shetty N. Consanguinity and ocular genetic diseases in South India: analysis of a five-year study. *Community Genet* (2002) 5(3):182–5. doi:10.1159/000066334
27. Kuntla S, Goli S, Shekar TV, Doshi R. Consanguineous marriages and their effect on pregnancy outcomes in India. Presented at: XXVII IUSSP International Population Conference; Aug 26–31; Busan, South Korea (2013).
28. Rawat A, Vignesh P, Sharma A, Shandilya JK, Sharma M, Suri D, et al. Infection profile in chronic granulomatous disease: a 23-year experience from a tertiary care center in North India. *J Clin Immunol* (2017) 37(3):319–28. doi:10.1007/s10875-017-0382-x
29. Elbjeirami WM, Abdel-Rahman F, Hussein AA. Probability of finding an HLA-matched donor in immediate and extended families: the Jordanian experience. *Biol Blood Marrow Transplant* (2013) 19(2):221–6. doi:10.1016/j.bbmt.2012.09.009

30. Hajeer AH, Algattan M, Anizi A, Alaskar AS, Jarrar MS. Chances of finding a matched parent-child in hematopoietic stem cell transplantation in Saudi Arabia. *Am J Blood Res* (2012) 2(3):201-2